|
IL63907A0
(en)
|
1980-09-24 |
1981-12-31 |
Cetus Corp |
Diagnostic method and antibody probe for use therein
|
|
US4582788A
(en)
|
1982-01-22 |
1986-04-15 |
Cetus Corporation |
HLA typing method and cDNA probes used therein
|
|
ATE53862T1
(de)
|
1982-01-22 |
1990-06-15 |
Cetus Corp |
Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel.
|
|
US4683194A
(en)
|
1984-05-29 |
1987-07-28 |
Cetus Corporation |
Method for detection of polymorphic restriction sites and nucleic acid sequences
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
CA1284931C
(en)
|
1986-03-13 |
1991-06-18 |
Henry A. Erlich |
Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
|
|
CA1338457C
(en)
|
1986-08-22 |
1996-07-16 |
Henry A. Erlich |
Purified thermostable enzyme
|
|
US5093330A
(en)
|
1987-06-15 |
1992-03-03 |
Ciba-Geigy Corporation |
Staurosporine derivatives substituted at methylamino nitrogen
|
|
US6605712B1
(en)
|
1990-12-20 |
2003-08-12 |
Arch Development Corporation |
Gene transcription and ionizing radiation: methods and compositions
|
|
JP2001523958A
(ja)
|
1997-03-21 |
2001-11-27 |
ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド |
免疫療法のｃｔｌａ−４結合ペプチド
|
|
EP1210428B1
(en)
|
1999-08-23 |
2015-03-18 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
|
IL148079A0
(en)
|
1999-08-24 |
2002-09-12 |
Medarex Inc |
Human ctla-4 antibodies and compositions containing the same
|
|
WO2003070887A2
(en)
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
ES2350687T3
(es)
|
2002-07-03 |
2011-01-26 |
Ono Pharmaceutical Co., Ltd. |
Composiciones de inmunopotenciación.
|
|
SI1853250T1
(sl)
|
2005-02-18 |
2012-01-31 |
Abraxis Bioscience Llc |
Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija
|
|
RU2494107C2
(ru)
|
2005-05-09 |
2013-09-27 |
Оно Фармасьютикал Ко., Лтд. |
Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
|
|
NZ568325A
(en)
|
2005-11-16 |
2011-05-27 |
S Bio Pte Ltd |
Macrocyclic oxygen linked pyrimidine derivatives
|
|
KR101511074B1
(ko)
|
2007-04-16 |
2015-04-13 |
애브비 인코포레이티드 |
7-치환된 인돌 Ｍｃｌ-1 억제제
|
|
HRP20131167T1
(hr)
|
2007-06-18 |
2014-01-03 |
Merck Sharp & Dohme B.V. |
Antitijela za humani receptor programirane smrti pd-1
|
|
GB0806652D0
(en)
|
2008-04-11 |
2008-05-14 |
Glaxo Group Ltd |
Anhydrous crystal form of orvepitant maleate
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
CN102203132A
(zh)
|
2008-08-25 |
2011-09-28 |
安普利穆尼股份有限公司 |
Pd-1拮抗剂的组合物和使用方法
|
|
AU2009333580B2
(en)
|
2008-12-09 |
2016-07-07 |
Genentech, Inc. |
Anti-PD-L1 antibodies and their use to enhance T-cell function
|
|
EP2418955A4
(en)
*
|
2009-04-15 |
2012-11-21 |
Poniard Pharmaceuticals Inc |
ORAL PICOPLATIN ANTITUMOR THERAPY WITH HIGH BIOAVAILABILITY
|
|
JP4965623B2
(ja)
|
2009-09-30 |
2012-07-04 |
インターナショナル・ビジネス・マシーンズ・コーポレーション |
所定のソフトウェアの実行パラメータを入力フィールドへ入力することを支援するための方法、システム、およびプログラム
|
|
US9120815B2
(en)
*
|
2010-02-05 |
2015-09-01 |
Tragara Pharmaceuticals, Inc. |
Solid state forms of macrocyclic kinase inhibitors
|
|
WO2011103016A2
(en)
|
2010-02-19 |
2011-08-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inhibiting ezh2
|
|
US9801853B2
(en)
|
2010-04-06 |
2017-10-31 |
Fred Hutchinson Cancer Research Center |
Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of MYC-driven tumor cells
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
BR112013005806B1
(pt)
|
2010-09-10 |
2022-05-10 |
Epizyme, Inc |
Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
|
|
US9175331B2
(en)
|
2010-09-10 |
2015-11-03 |
Epizyme, Inc. |
Inhibitors of human EZH2, and methods of use thereof
|
|
US8841418B2
(en)
|
2011-07-01 |
2014-09-23 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to TIM3
|
|
WO2013043569A1
(en)
|
2011-09-20 |
2013-03-28 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
|
CA2850570A1
(en)
|
2011-09-30 |
2013-04-04 |
Glaxosmithkline Llc |
Methods of treating cancer
|
|
HRP20201595T1
(hr)
|
2011-11-28 |
2020-12-11 |
Merck Patent Gmbh |
Anti-pd-l1 protutijela i njihova uporaba
|
|
EP3536314A1
(en)
|
2012-03-12 |
2019-09-11 |
Epizyme, Inc. |
Inhibitors of human ezh2, and methods of use thereof
|
|
CN113967253A
(zh)
|
2012-05-15 |
2022-01-25 |
百时美施贵宝公司 |
通过破坏pd-1/pd-l1信号传输的免疫治疗
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
CA2916638C
(en)
|
2012-07-31 |
2021-01-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of the immune response
|
|
KR20230156450A
(ko)
|
2012-10-15 |
2023-11-14 |
에피자임, 인코포레이티드 |
암을 치료하는 방법
|
|
SI2958916T1
(sl)
|
2013-02-21 |
2018-11-30 |
Pfizer Inc. |
Trdne oblike selektivnih zaviralcev CDK4/6
|
|
EA037554B1
(ru)
|
2013-03-15 |
2021-04-13 |
Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Анти-lag-3 связывающие белки
|
|
NZ718821A
(en)
|
2013-09-11 |
2022-07-01 |
Medimmune Ltd |
Anti-b7-h1 antibodies for treating tumors
|
|
EP3113798B1
(en)
|
2014-03-07 |
2019-06-05 |
University Health Network |
Methods and compositions for modifying the immune response
|
|
US20150259420A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
KR20240010105A
(ko)
|
2014-03-14 |
2024-01-23 |
아지오스 파마슈티컬스 아이엔씨. |
치료적으로 활성인 화합물의 약제학적 조성물
|
|
SG11201808306PA
(en)
|
2016-03-24 |
2018-10-30 |
Tragara Pharmaceuticals Inc |
Treatment of cancer with tg02
|
|
RU2020111019A
(ru)
|
2017-08-18 |
2021-09-20 |
Трагара Фармасьютикалз, Инк. |
Полиморфная форма tg02
|